0.14
-17.65%
Close of 6 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Star Combo Pharma
Its shares trade on ASX under the ticker S66.AX. It has been listed since 16 May 2018. In the fiscal year to 30 June 2026, it reported revenue of A$23.6m and net income of A$394,606. At that date it held total assets of A$50.1m and shareholders' equity of A$38.8m.
Star Combo Pharma Ltd. engages in the manufacture and distribution of vitamis, dietary supplements, and skincare products. The company is headquartered in Sydney, New South Wales. The company went IPO on 2018-05-16. The firm operates through two segments: Star Combo business and Austoyou retail. The Star Combo business segment includes developing, manufacturing, marketing and sales of natural health supplements and skincare products. The Austoyou retail business segment is made up of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers. The Company’s product categories include Costar, Living Healthy, Amax and J&K. The firm also provides Original Equipment Manufacturer (OEM) Services and Quality Assurance. The Company’s wholly owned subsidiaries include CoStar Pharma Laboratory Pty Ltd and Star Combo Australia Pty Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 16 May 2018
- Website
- starcombo.com.au ↗
Leadership
Pay as last reported
- Mr. Richard AllelyNon-Executive Independent Chairman of the BoardA$100,456
- Ms. Su ZhangChief Executive Officer, DirectorA$193,833
- Mr. James NiChief Financial OfficerA$4,071
- Mr. Jinxing ZhangManaging Director, Director, since 2016A$198,198
- Mr. Patrick RaperCompany Secretary
- Mr. Jialong DingNon-Executive Director
- Ms. Wei HanNon-Executive Director
- Dr. Ziye SuiNon-Executive DirectorA$19,800
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Star Combo Pharma manufactures vitamins and skincare products for global markets.
- The Austoyou retail segment connects Australian goods directly to Chinese consumers.
- CoStar Pharma Laboratory provides essential OEM services and quality assurance support.
Weaknesses
- The company relies heavily on the Australia-China e-commerce platform for sales.
- Consumer Staples sector faces intense competition from established global brands.
- Regulatory compliance costs may increase due to cross-border trade complexities.
Opportunities
- Growing demand for natural health supplements in the Chinese market.
- Expansion of the Austoyou platform could reach more international buyers.
- Increasing consumer interest in skincare products drives segment growth potential.
Threats
- Trade tensions between Australia and China may disrupt export flows.
- Economic downturns could reduce discretionary spending on dietary supplements.
- Supply chain disruptions might impact the manufacturing of vitamin products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.